Senthil Damodaran, MD, PhD, on Futibatinib Plus Fulvestrant in Advanced Breast Cancer: Clinical Implications

Posted: Monday, March 11, 2024

Senthil Damodaran, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the clinical implications of findings from the FOENIX-MBC2 study. This trial examined the efficacy and safety of the kinase inhibitor futibatinib in patients with locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring high-level FGFR1 gene amplification.

---